Deals

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal
BioMarin PharmaceuticalNASDAQ: BMRN

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that it has entered into an exclusive worldwide (excluding Korea) license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to co‑develop and…

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Kangtai Biological Co‑founds Beijing Laboratory to Advance Synthetic Immunology and Vaccine Manufacturing
AIKangtai Biological Products

Kangtai Biological Co‑founds Beijing Laboratory to Advance Synthetic Immunology and Vaccine Manufacturing

Huadong Medicine Licenses MC2's PAD‑Based Biomee Skincare for Greater China
Huadong MedicineMC2 Therapeutics

Huadong Medicine Licenses MC2’s PAD‑Based Biomee Skincare for Greater China

Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion
Aspen Pharmacare

Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion
NMPA

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

Show More